Presolver Pharmaceuticals Announces Appeal to German Federal Supreme Court Regarding Arbitration Case
Presolver Pharmaceuticals announced its appeal to the German Federal Supreme Court concerning an arbitration case with AOP Orphan Pharmaceuticals GmbH, following the rejection of its annulment request by the Frankfurt Higher Court.
📋 Article Processing Timeline
- 📰 Published: April 30, 2026 at 09:00
- 🔍 Collected: May 4, 2026 at 08:00 (95h 0m after Published)
- 🤖 AI Analyzed: May 4, 2026 at 08:01 (1 min after Collected)
1. Parties to the legal event:
Petitioner: Presolver Pharmaceuticals Co., Ltd.
Respondent: AOP Orphan Pharmaceuticals GmbH (hereinafter referred to as AOP)
2. Court Name or Disposing Authority of the Legal Event: German Federal Supreme Court
3. Case Number of the Relevant Document: None yet
4. Date of Fact Occurrence: 115/04/30
5. Cause of Occurrence (including subject of dispute):
Regarding the arbitration case between our company and AOP, our company received a Partial Final Award from the International Court of Arbitration (ICC) on February 17, 2025. Our company legally filed a request with the Frankfurt Higher Court of Germany to annul part of the partial arbitral award. The Frankfurt Higher Court of Germany dismissed our company's request for annulment on April 24, 2026.
6. Handling Process:
Regarding the ruling by the Frankfurt Higher Court of Germany that dismissed our company's request for annulment, as our company's core legal claims and important evidence were not adequately reviewed according to law, our company has legally appealed to the German Federal Supreme Court.
7. Impact on Company's Financial and Business Operations and Estimated Impact Amount:
Currently, there is no impact on the company's financial and business operations.
8. Response Measures and Improvement Status: None.
9. Other Matters to be Noted (If the subject of the event occurrence or resolution is a company with publicly issued shares or above, this material information also meets the criteria for matters that have a significant impact on shareholder equity or securities prices as stipulated in Article 7, Clause 2 of the Enforcement Rules of the Securities Transaction Act):
None.
Petitioner: Presolver Pharmaceuticals Co., Ltd.
Respondent: AOP Orphan Pharmaceuticals GmbH (hereinafter referred to as AOP)
2. Court Name or Disposing Authority of the Legal Event: German Federal Supreme Court
3. Case Number of the Relevant Document: None yet
4. Date of Fact Occurrence: 115/04/30
5. Cause of Occurrence (including subject of dispute):
Regarding the arbitration case between our company and AOP, our company received a Partial Final Award from the International Court of Arbitration (ICC) on February 17, 2025. Our company legally filed a request with the Frankfurt Higher Court of Germany to annul part of the partial arbitral award. The Frankfurt Higher Court of Germany dismissed our company's request for annulment on April 24, 2026.
6. Handling Process:
Regarding the ruling by the Frankfurt Higher Court of Germany that dismissed our company's request for annulment, as our company's core legal claims and important evidence were not adequately reviewed according to law, our company has legally appealed to the German Federal Supreme Court.
7. Impact on Company's Financial and Business Operations and Estimated Impact Amount:
Currently, there is no impact on the company's financial and business operations.
8. Response Measures and Improvement Status: None.
9. Other Matters to be Noted (If the subject of the event occurrence or resolution is a company with publicly issued shares or above, this material information also meets the criteria for matters that have a significant impact on shareholder equity or securities prices as stipulated in Article 7, Clause 2 of the Enforcement Rules of the Securities Transaction Act):
None.